|本期目录/Table of Contents|

[1]王婵,钟波,吕正兵,等.条纹斑竹鲨的抗乙肝表面抗原的单域抗体筛选与重组抗体活性探究[J].浙江理工大学学报,2022,47-48(自科一):115-122.
 WANG Chan,ZHONG Bo,L  Zhengbing,et al.The screening of Anti HBsAgsingle domain antibody from Chiloscyllium plagiosum and the study on the activity of  recombinant antibody[J].Journal of Zhejiang Sci-Tech University,2022,47-48(自科一):115-122.
点击复制

条纹斑竹鲨的抗乙肝表面抗原的单域抗体筛选与重组抗体活性探究()
分享到:

浙江理工大学学报[ISSN:1673-3851/CN:33-1338/TS]

卷:
第47-48卷
期数:
2022年自科第一期
页码:
115-122
栏目:
出版日期:
2022-01-31

文章信息/Info

Title:
The screening of Anti HBsAgsingle domain antibody from Chiloscyllium plagiosum and the study on the activity of  recombinant antibody
文章编号:
1673-3851 (2022) 01-0115-08
作者:
王婵钟波吕正兵王磊陈剑清
浙江理工大学生命科学与医药学院,杭州 310018
Author(s):
WANG Chan ZHONG Bo L  Zhengbing WANG Lei CHEN Jianqing
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China
关键词:
单域抗体条纹斑竹鲨乙肝表面抗原新抗原受体可变区重组表达
分类号:
Q51
文献标志码:
A
摘要:
对免疫HBsAg ad亚型抗原的条纹斑竹鲨中血清、脾脏和淋巴细胞进行多组学测序结果综合分析筛选出特异性序列,构建重组表达质粒pET Duet his sumoAntiHBsAgS1、pETDuethissumoAntiHBsAgS2,分别转化大肠杆菌BL21(DE3),并诱导表达以及纯化重组单域抗体,通过ELISA和细胞水平检测重组单域抗体的活性。结果表明:通过生物信息学分析筛选出2条特异性序列,在16 ℃、0-5 mmol/L诱导剂条件下可获得2 mg/mL以上的重组蛋白;ELISA检测显示均与HBsAg具有较好的结合力,细胞水平活性分析得到Anti HBsAgS1具有较好的病毒抑制效果和生物学活性。该研究结果为其他抗原的特异性抗体筛选提供理论参考。

参考文献/References:

[1] Demosthenes J P, Sachithanandham J, Fletcher G J, et al. Characteristics of treatmentnave HBVinfected individuals with HIV1 coinfection: A crosssectional study from South India[J]. Indian Journal of Medical Microbiology, 2019, 37(2): 219-224.
[2] Foreman K J, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and allcause and causespecific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories[J]. The Lancet, 2018, 392(10159): 2052-2090.
[3] Li C, Wang Y, Liu T T, et al. An E. coli produced singlechain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion[J]. Antiviral Research, 2019, 162(1): 118-129.
[4] Zhang L, Sang W O. Production and characterization of monoclonal antibodies against primo vascular system of rat[J]. Journal of Acupuncture and Meridian Studies, 2020, 13(3): 110-115.
[5] Tai W, Zhang X, He Y, et al. Identification of SARSCoV RBDtargeting monoclonal antibodies with crossreactive or neutralizing activity against SARSCoV2[J]. Antiviral Research, 2020, 179(1): 1-23.
[6] Pimm M V. Drugmonoclonal antibody conjugates for cancer therapy: potentials and limitations[J]. Critical Reviews in Therapeutic Drug Carrier System, 1988, 5(3): 189-227.
[7] Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy[J]. Biologics, 2019, 13(1): 33-51.
[8] Wesolowski J, Alzogaray V, Reyelt J, et al. Single domain antibodies: Promising experimental and therapeutic tools in infection and immunity[J]. Medical Microbiology and Immunology, 2009, 198(3): 157-174.
[9] Saerens D, Pellis M, Loris R, et al. Identification of a universal VHH framework to graft noncanonical antigenbinding loops of camel singledomain antibodies[J]. Journal of Molecular Biology, 2005, 352(3): 597-607.
[10] Zare H, Aghamollaei H, Hosseindokht M, et al. Nanobodies, the potent agents to detect and treat the coronavirus infections: A systematic review[J]. Molecular Cellular Probes, 2021, 55(5):1-15.

备注/Memo

备注/Memo:
收稿日期:2021-06-02
网络出版日期:2021-09-16
基金项目:国家级大学生创新创业训练项目(201910338029)
作者简介:王婵(1995-),女,河南南阳人,硕士研究生,主要从事生物制药方面的研究
通信作者:陈剑清,E-mail:cjqgqj@126.com
更新日期/Last Update: 2022-03-08